Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

341 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pembrolizumab plus pomalidomide and dexamethasone for relapsed or refractory multiple myeloma (KEYNOTE-183): subgroup analysis in Japanese patients.
Matsumoto M, Suzuki K, Kuroda J, Taniwaki M, Sunami K, Kosugi H, Ando K, Maruyama D, Tobinai K, Kher U, Farooqui M, Liao J, Marinello P, Matsuda K, Koh Y, Shimamoto T, Iida S. Matsumoto M, et al. Among authors: sunami k. Int J Hematol. 2021 Jun;113(6):777-784. doi: 10.1007/s12185-021-03139-1. Epub 2021 Apr 15. Int J Hematol. 2021. PMID: 33856638 Clinical Trial.
Use of micafungin versus fluconazole for antifungal prophylaxis in neutropenic patients receiving hematopoietic stem cell transplantation.
Hiramatsu Y, Maeda Y, Fujii N, Saito T, Nawa Y, Hara M, Yano T, Asakura S, Sunami K, Tabayashi T, Miyata A, Matsuoka KI, Shinagawa K, Ikeda K, Matsuo K, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Hiramatsu Y, et al. Among authors: sunami k. Int J Hematol. 2008 Dec;88(5):588-595. doi: 10.1007/s12185-008-0196-y. Epub 2008 Nov 29. Int J Hematol. 2008. PMID: 19039629 Clinical Trial.
The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis.
Nishimori H, Matsuo K, Maeda Y, Nawa Y, Sunami K, Togitani K, Takimoto H, Hiramatsu Y, Kiguchi T, Yano T, Yamane H, Tabayashi T, Takeuchi M, Makita M, Sezaki N, Yamasuji Y, Sugiyama H, Tabuchi T, Kataoka I, Fujii N, Ishimaru F, Shinagawa K, Ikeda K, Hara M, Yoshino T, Tanimoto M; West-Japan Hematology and Oncology Group (West-JHOG). Nishimori H, et al. Among authors: sunami k. Int J Hematol. 2009 Apr;89(3):326-331. doi: 10.1007/s12185-009-0259-8. Epub 2009 Mar 27. Int J Hematol. 2009. PMID: 19326060
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.
Sunami K, Shinagawa K, Sawamura M, Sakai A, Saburi Y, Imamura Y, Mizuno I, Tamaki S, Kamimura T, Tsuda H, Gondo H, Hino N, Shimazaki C, Miyata A, Tajima F, Takemoto Y, Miwa A, Chou T, Harada M. Sunami K, et al. Int J Hematol. 2009 Dec;90(5):635-642. doi: 10.1007/s12185-009-0445-8. Epub 2009 Nov 21. Int J Hematol. 2009. PMID: 19936876 Clinical Trial.
Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
Ennishi D, Maeda Y, Niitsu N, Kojima M, Izutsu K, Takizawa J, Kusumoto S, Okamoto M, Yokoyama M, Takamatsu Y, Sunami K, Miyata A, Murayama K, Sakai A, Matsumoto M, Shinagawa K, Takaki A, Matsuo K, Kinoshita T, Tanimoto M. Ennishi D, et al. Among authors: sunami k. Blood. 2010 Dec 9;116(24):5119-25. doi: 10.1182/blood-2010-06-289231. Epub 2010 Sep 7. Blood. 2010. PMID: 20823454 Free article.
A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma.
Takamatsu Y, Sunami K, Hata H, Nagafuji K, Choi I, Higuchi M, Uozumi K, Masaki Y, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: sunami k. Int J Hematol. 2010 Oct;92(3):503-9. doi: 10.1007/s12185-010-0673-y. Epub 2010 Sep 8. Int J Hematol. 2010. PMID: 20824401 Clinical Trial.
Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups.
Kihara R, Watanabe T, Yano T, Uike N, Okamura S, Kawano F, Hanada S, Sunami K, Inoue N, Sawamura M, Yoshida S, Shimomura T, Kitano K, Kojima Y, Horibe K, Nagai H. Kihara R, et al. Among authors: sunami k. Int J Hematol. 2013 Jan;97(1):98-102. doi: 10.1007/s12185-012-1243-2. Epub 2012 Dec 15. Int J Hematol. 2013. PMID: 23243003
Bortezomib, doxorubicin and intermediate-dose dexamethasone (iPAD) therapy for relapsed or refractory multiple myeloma: a multicenter phase 2 study.
Takamatsu Y, Sunami K, Muta T, Morimoto H, Miyamoto T, Higuchi M, Uozumi K, Hata H, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: sunami k. Int J Hematol. 2013 Aug;98(2):179-85. doi: 10.1007/s12185-013-1389-6. Epub 2013 Jul 6. Int J Hematol. 2013. PMID: 23832805 Clinical Trial.
Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era.
Takamatsu H, Honda S, Miyamoto T, Yokoyama K, Hagiwara S, Ito T, Tomita N, Iida S, Iwasaki T, Sakamaki H, Suzuki R, Sunami K. Takamatsu H, et al. Among authors: sunami k. Cancer Sci. 2015 Feb;106(2):179-85. doi: 10.1111/cas.12594. Epub 2015 Feb 6. Cancer Sci. 2015. PMID: 25530023 Free PMC article.
341 results